Zhu Yi
$15.3B
Born
Dec 01, 1963
Age
62
Source of Wealth
Pharmaceuticals
Residence
Chengdu, Sichuan
Citizenship
China
Marital Status
Children
0
Education
- Zhu Yi is the chairman of Biokin Pharmaceutical, a developer of drugs including anesthesia injections, cancer drugs as well as traditional Chinese medicine treatments.
- The company went public in Shanghai in 2023, raising $136 million; it has been seeking a Hong Kong IPO since 2024.
- Biokin's U.S. subsidiary SystImmune signed in 2023 an $8.4 billion deal with Bristol Myers Squibb to jointly develop and commercialize a potential cancer treatment worldwide.
- Zhu taught immunology and microbiology at West China University of Medical Sciences before striking out on his own.
- Zhu has a master's in biology from Fudan University and a doctorate in management from Sichuan University.
| Exchange | Ticker | Company Name | Number Of Shares | Share Price | Currency Code |
|---|